NasdaqGM:NRIXBiotechs
Is Nurix Therapeutics (NRIX) Overvalued As Its Roche Deal Lifts Hopes For Future Growth?
Nurix Therapeutics (NRIX) stock moved after investors reacted to a new collaboration with Roche to co-develop and co-commercialize bexobrutideg for blood cancers and other conditions, supported by significant upfront and potential milestone payments.
See our latest analysis for Nurix Therapeutics.
The Roche collaboration comes at a time when Nurix Therapeutics has seen momentum build, with the latest 7 day share price return of 30.48% and a 1 year total shareholder return of 96.74% following...